KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) Interest Expenses (2017 - 2022)

Sarepta Therapeutics has reported Interest Expenses over the past 6 years, most recently at $6.7 million for Q4 2022.

  • For Q4 2022, Interest Expenses fell 40.09% year-over-year to $6.7 million; the TTM value through Sep 2023 reached $6.7 million, down 87.07%, while the annual FY2023 figure was $22.0 million, 58.67% down from the prior year.
  • Interest Expenses for Q4 2022 was $6.7 million at Sarepta Therapeutics, up from $6.3 million in the prior quarter.
  • Over five years, Interest Expenses peaked at $25.7 million in Q4 2020 and troughed at $172000.0 in Q1 2019.
  • A 5-year average of $11.8 million and a median of $10.9 million in 2018 define the central range for Interest Expenses.
  • Biggest five-year swings in Interest Expenses: tumbled 97.75% in 2019 and later surged 7815.7% in 2020.
  • Year by year, Interest Expenses stood at $7.2 million in 2018, then grew by 15.74% to $8.4 million in 2019, then skyrocketed by 206.85% to $25.7 million in 2020, then plummeted by 56.64% to $11.2 million in 2021, then plummeted by 40.09% to $6.7 million in 2022.
  • Business Quant data shows Interest Expenses for SRPT at $6.7 million in Q4 2022, $6.3 million in Q3 2022, and $17.0 million in Q2 2022.